Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001140361-23-051165
Filing Date
2023-11-02
Accepted
2023-11-02 16:30:42
Documents
1
Group Members
DAVID C. OTTO. ANDREAS HALVORSENROSE S. SHABETVIKING GLOBAL EQUITIES II LPVIKING GLOBAL EQUITIES MASTER LTD.VIKING GLOBAL PERFORMANCE LLCVIKING LONG FUND GP LLCVIKING LONG FUND MASTER LTD.

Document Format Files

Seq Description Document Type Size
1 SC 13G ef20013879_sc13g.htm SC 13G 283683
  Complete submission text file 0001140361-23-051165.txt   285515
Mailing Address 600 WASHINGTON BLVD. FLOOR 11 STAMFORD CT 06901
Business Address 600 WASHINGTON BLVD. FLOOR 11 STAMFORD CT 06901 212-672-7050
VIKING GLOBAL INVESTORS LP (Filed by) CIK: 0001103804 (see all company filings)

EIN.: 134055118 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G

Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Subject) CIK: 0001607678 (see all company filings)

EIN.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-88828 | Film No.: 231372897
SIC: 2834 Pharmaceutical Preparations